Phase 4 Obesity Trial, Recruiting NCT06739473 Sponsor: Turku University Hospital Condition: Obesity
Back to Obesity

Phase 4 Obesity Trial, Recruiting

NCT06739473
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 20 and 60 years old
  • Your body weight falls into one of two specific ranges: either a healthy/normal weight (BMI 18.5–25) or obese (BMI above 30)
  • Women who could become pregnant must be using hormonal birth control (such as the pill or a hormonal coil)

Who may not be able to join:

  • People in the normal-weight group who have a history of obesity or type 2 diabetes
  • People in the obese group who currently use or have previously used certain diabetes or weight-loss medications called GLP-1 agonists (such as Ozempic or Wegovy) or insulin
  • Anyone with a history of eating disorders
  • People who smoke, use illegal drugs, or drink alcohol excessively
  • Anyone who has previously taken part in a PET scan study
  • Anyone who has previously been exposed to significant amounts of radiation
  • People who experience claustrophobia (fear of enclosed spaces, such as a scanner)
  • Anyone — male or female — who is actively planning to have a child in the near future
  • Anyone whose overall health condition, in the opinion of the study doctor, could make participation unsafe or affect the study results (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 5 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Lauri Nummenmaa, Professor, University of Turku

Phone: 358+23139857

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Turku University Hospital
Registry
ClinicalTrials.gov
Start date
25 January 2023
Est. completion
1 December 2024

Where this trial is recruiting

🇫🇮 Finland

Primary endpoints

Insulin-induced change in tissue blood flow

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 5 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov